Compounds > nafimidone alcohol
Page last updated: 2024-12-07

nafimidone alcohol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nafimidone alcohol: nafimidone metabolite; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID130368
CHEMBL ID350367
SCHEMBL ID11247208
MeSH IDM0148956

Synonyms (16)

Synonym
71009-17-1
1-(2-hydroxy-2-(2-naphthyl)ethyl)imidazole
1h-imidazole-1-ethanol, alpha-2-naphthalenyl-
alpha-2-naphthalenyl-1h-imidazole-1-ethanol
brn 0521937
nafimidone alcohol
CHEMBL350367
2-imidazol-1-yl-1-naphthalen-2-ylethanol
AKOS005947514
SCHEMBL11247208
1-[2-hydroxy-2-(2-naphthyl)ethyl]imidazole
1-[2-(2-naphthyl)-2-hydroxyethyl]imidazole
LFAPKHXSAABGPQ-UHFFFAOYSA-N
1-[2-hydroxy-2-(2-naphthyl)-ethyl]imidazole
DTXSID80991301
2-(1h-imidazol-1-yl)-1-(naphthalen-2-yl)ethan-1-ol

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID134730Lethal dose was measured in mice after ip administration.1981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
1-(Naphthylalkyl)-1H-imidazole derivatives, a new class of anticonvulsant agents.
AID129799Compound was evaluated for anticonvulsant activity by maximal electroshock assay(MES) in mice after ip administration; 55-1101981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
1-(Naphthylalkyl)-1H-imidazole derivatives, a new class of anticonvulsant agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (75.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.34 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
imidazole
imidazole: RN given refers to parent cpd. 1H-imidazole : An imidazole tautomer which has the migrating hydrogen at position 1.		2.0510imidazole
phenytoin
[no description available]		1.9610imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
naphazoline
Naphazoline: An adrenergic vasoconstrictor agent used as a decongestant.		2.6830naphthalenes
phenobarbital
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.		1.9610barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
2-acetylnaphthalene
2-acetylnaphthalene : A naphthyl ketone that is naphthalene substituted at position 2 by an acetyl group.		2.0510naphthyl ketone
nafimidone
nafimidone: RN given refers to parent cpd		7.3720
ConditionIndicatedRelationship StrengthStudiesTrials
Absence Seizure
[description not available]		02.0510
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		02.0510
Chronic Illness
[description not available]		01.9710
Aura
[description not available]		01.9710
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		01.9710
Epilepsy
A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)		01.9710